An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer
Armin Mooranian,1 Rebecca Negrulj,1 Nigel Chen-Tan,2 Gerald F Watts,3 Frank Arfuso,4 Hani Al-Salami11Biotechnology and Drug Development Research Laboratory, School of Pharmacy, Curtin Health Innovation Research Institute, Biosciences Research Precinct, Curtin University, 2Faculty of Science and Engi...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2014-09-01
|
| Series: | Drug Design, Development and Therapy |
| Online Access: | http://www.dovepress.com/an-optimized-probucol-microencapsulated-formulation-integrating-a-seco-peer-reviewed-article-DDDT |
| _version_ | 1811265601931313152 |
|---|---|
| author | Mooranian A Negrulj R Chen-Tan N Watts GF Arfuso F Al-Salami H |
| author_facet | Mooranian A Negrulj R Chen-Tan N Watts GF Arfuso F Al-Salami H |
| author_sort | Mooranian A |
| collection | DOAJ |
| description | Armin Mooranian,1 Rebecca Negrulj,1 Nigel Chen-Tan,2 Gerald F Watts,3 Frank Arfuso,4 Hani Al-Salami11Biotechnology and Drug Development Research Laboratory, School of Pharmacy, Curtin Health Innovation Research Institute, Biosciences Research Precinct, Curtin University, 2Faculty of Science and Engineering, Curtin University, 3School of Medicine and Pharmacology, Royal Perth Hospital, University of Western Australia, 4School of Biomedical Science, Curtin Health Innovation Research Institute, Biosciences Research Precinct, Curtin University, Perth, AustraliaAbstract: The authors have previously designed, developed, and characterized a novel microencapsulated formulation as a platform for the targeted delivery of therapeutics in an animal model of type 2 diabetes, using the drug probucol (PB). The aim of this study was to optimize PB microcapsules by incorporating the bile acid deoxycholic acid (DCA), which has good permeation-enhancing properties, and to examine its effect on microcapsules’ morphology, rheology, structural and surface characteristics, and excipients’ chemical and thermal compatibilities. Microencapsulation was carried out using a BÜCHI-based microencapsulating system established in the authors’ laboratory. Using the polymer sodium alginate (SA), two microencapsulated formulations were prepared: PB-SA (control) and PB-DCA-SA (test) at a constant ratio (1:30 and 1:3:30, respectively). Complete characterization of the microcapsules was carried out. The incorporation of DCA resulted in better structural and surface characteristics, uniform morphology, and stable chemical and thermal profiles, while size and rheological parameters remained similar to control. In addition, PB-DCA-SA microcapsules showed good excipients’ compatibilities, which were supported by data from differential scanning calorimetry, Fourier transform infrared spectroscopy, scanning electron microscopy, and energy dispersive X-ray studies, suggesting microcapsule stability. Hence, PB-DCA-SA microcapsules have good rheological and compatibility characteristics and may be suitable for the oral delivery of PB in type 2 diabetes.Keywords: artificial cell microencapsulation, diabetes, bile acids, probucol, antioxidant, anti-inflammatory, BÜCHI B390 |
| first_indexed | 2024-04-12T20:26:48Z |
| format | Article |
| id | doaj.art-1329ef9a473a461fa6aedd7a0aacfffc |
| institution | Directory Open Access Journal |
| issn | 1177-8881 |
| language | English |
| last_indexed | 2024-04-12T20:26:48Z |
| publishDate | 2014-09-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj.art-1329ef9a473a461fa6aedd7a0aacfffc2022-12-22T03:17:50ZengDove Medical PressDrug Design, Development and Therapy1177-88812014-09-012014default1673168318565An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancerMooranian ANegrulj RChen-Tan NWatts GFArfuso FAl-Salami HArmin Mooranian,1 Rebecca Negrulj,1 Nigel Chen-Tan,2 Gerald F Watts,3 Frank Arfuso,4 Hani Al-Salami11Biotechnology and Drug Development Research Laboratory, School of Pharmacy, Curtin Health Innovation Research Institute, Biosciences Research Precinct, Curtin University, 2Faculty of Science and Engineering, Curtin University, 3School of Medicine and Pharmacology, Royal Perth Hospital, University of Western Australia, 4School of Biomedical Science, Curtin Health Innovation Research Institute, Biosciences Research Precinct, Curtin University, Perth, AustraliaAbstract: The authors have previously designed, developed, and characterized a novel microencapsulated formulation as a platform for the targeted delivery of therapeutics in an animal model of type 2 diabetes, using the drug probucol (PB). The aim of this study was to optimize PB microcapsules by incorporating the bile acid deoxycholic acid (DCA), which has good permeation-enhancing properties, and to examine its effect on microcapsules’ morphology, rheology, structural and surface characteristics, and excipients’ chemical and thermal compatibilities. Microencapsulation was carried out using a BÜCHI-based microencapsulating system established in the authors’ laboratory. Using the polymer sodium alginate (SA), two microencapsulated formulations were prepared: PB-SA (control) and PB-DCA-SA (test) at a constant ratio (1:30 and 1:3:30, respectively). Complete characterization of the microcapsules was carried out. The incorporation of DCA resulted in better structural and surface characteristics, uniform morphology, and stable chemical and thermal profiles, while size and rheological parameters remained similar to control. In addition, PB-DCA-SA microcapsules showed good excipients’ compatibilities, which were supported by data from differential scanning calorimetry, Fourier transform infrared spectroscopy, scanning electron microscopy, and energy dispersive X-ray studies, suggesting microcapsule stability. Hence, PB-DCA-SA microcapsules have good rheological and compatibility characteristics and may be suitable for the oral delivery of PB in type 2 diabetes.Keywords: artificial cell microencapsulation, diabetes, bile acids, probucol, antioxidant, anti-inflammatory, BÜCHI B390http://www.dovepress.com/an-optimized-probucol-microencapsulated-formulation-integrating-a-seco-peer-reviewed-article-DDDT |
| spellingShingle | Mooranian A Negrulj R Chen-Tan N Watts GF Arfuso F Al-Salami H An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer Drug Design, Development and Therapy |
| title | An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer |
| title_full | An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer |
| title_fullStr | An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer |
| title_full_unstemmed | An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer |
| title_short | An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer |
| title_sort | optimized probucol microencapsulated formulation integrating a secondary bile acid deoxycholic acid as a permeation enhancer |
| url | http://www.dovepress.com/an-optimized-probucol-microencapsulated-formulation-integrating-a-seco-peer-reviewed-article-DDDT |
| work_keys_str_mv | AT mooraniana anoptimizedprobucolmicroencapsulatedformulationintegratingasecondarybileaciddeoxycholicacidasapermeationenhancer AT negruljr anoptimizedprobucolmicroencapsulatedformulationintegratingasecondarybileaciddeoxycholicacidasapermeationenhancer AT chentann anoptimizedprobucolmicroencapsulatedformulationintegratingasecondarybileaciddeoxycholicacidasapermeationenhancer AT wattsgf anoptimizedprobucolmicroencapsulatedformulationintegratingasecondarybileaciddeoxycholicacidasapermeationenhancer AT arfusof anoptimizedprobucolmicroencapsulatedformulationintegratingasecondarybileaciddeoxycholicacidasapermeationenhancer AT alsalamih anoptimizedprobucolmicroencapsulatedformulationintegratingasecondarybileaciddeoxycholicacidasapermeationenhancer AT mooraniana optimizedprobucolmicroencapsulatedformulationintegratingasecondarybileaciddeoxycholicacidasapermeationenhancer AT negruljr optimizedprobucolmicroencapsulatedformulationintegratingasecondarybileaciddeoxycholicacidasapermeationenhancer AT chentann optimizedprobucolmicroencapsulatedformulationintegratingasecondarybileaciddeoxycholicacidasapermeationenhancer AT wattsgf optimizedprobucolmicroencapsulatedformulationintegratingasecondarybileaciddeoxycholicacidasapermeationenhancer AT arfusof optimizedprobucolmicroencapsulatedformulationintegratingasecondarybileaciddeoxycholicacidasapermeationenhancer AT alsalamih optimizedprobucolmicroencapsulatedformulationintegratingasecondarybileaciddeoxycholicacidasapermeationenhancer |